JP2007533733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533733A5 JP2007533733A5 JP2007509061A JP2007509061A JP2007533733A5 JP 2007533733 A5 JP2007533733 A5 JP 2007533733A5 JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007533733 A5 JP2007533733 A5 JP 2007533733A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- betahistine
- pharmaceutical composition
- medicament
- antipsychotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 21
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 229960004536 betahistine Drugs 0.000 claims 9
- 229940001470 psychoactive drug Drugs 0.000 claims 9
- 239000004089 psychotropic agent Substances 0.000 claims 9
- 230000000561 anti-psychotic effect Effects 0.000 claims 8
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical group NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 230000004584 weight gain Effects 0.000 claims 6
- 235000019786 weight gain Nutrition 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 4
- 229960005017 olanzapine Drugs 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 239000003270 steroid hormone Substances 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 229940096699 bile acid sequestrants Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000005686 eating Nutrition 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL16159504A IL161595A0 (en) | 2004-04-22 | 2004-04-22 | Betahistine as a weight management agent |
| US67029005P | 2005-04-12 | 2005-04-12 | |
| PCT/IL2005/000440 WO2005101979A2 (en) | 2004-04-22 | 2005-04-21 | Method of food intake management |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007533733A JP2007533733A (ja) | 2007-11-22 |
| JP2007533733A5 true JP2007533733A5 (enExample) | 2008-05-29 |
Family
ID=35197421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509061A Pending JP2007533733A (ja) | 2004-04-22 | 2005-04-21 | 食物摂取管理の方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20060084686A1 (enExample) |
| EP (1) | EP1737454A4 (enExample) |
| JP (1) | JP2007533733A (enExample) |
| KR (1) | KR20060134041A (enExample) |
| BR (1) | BRPI0506807A (enExample) |
| CA (1) | CA2553309A1 (enExample) |
| EA (1) | EA200601414A1 (enExample) |
| IL (1) | IL176793A0 (enExample) |
| NO (1) | NO20063221L (enExample) |
| WO (1) | WO2005101979A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080051440A1 (en) * | 2004-04-22 | 2008-02-28 | Mor Research Applications Ltd. | Compositions for weight management |
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| CA2553309A1 (en) * | 2004-04-22 | 2005-11-03 | Mor Research Applications Ltd. | Method of food intake management |
| WO2007020079A2 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Orally disintegratable simvastatin tablets |
| US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
| US8748419B2 (en) * | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| CN101472476B (zh) * | 2006-06-16 | 2013-10-30 | 泰拉科斯有限公司 | 毒蕈碱型受体m1拮抗剂在制备治疗肥胖症的药物中的应用 |
| US20080033019A1 (en) * | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| RU2492858C2 (ru) * | 2007-04-11 | 2013-09-20 | Омерос Корпорейшн | Композиции и способы профилактики и лечения зависимостей |
| WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
| US8586634B2 (en) * | 2007-06-15 | 2013-11-19 | University Of Florida Research Foundation, Inc. | Therapeutic compounds |
| WO2009143572A1 (en) | 2008-05-27 | 2009-12-03 | The University Of Melbourne | Methods of treating mammals with eustachian tube dysfunctions |
| US20120115778A1 (en) * | 2009-07-15 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2 |
| US20110021507A1 (en) * | 2009-07-22 | 2011-01-27 | Theracos, Inc. | Inhibiting antipsychotic-induced weight gain |
| CN102576384A (zh) * | 2009-10-13 | 2012-07-11 | 雀巢产品技术援助有限公司 | 用于评估膳食摄入量的系统以及使用的方法 |
| NZ600379A (en) | 2009-12-04 | 2014-05-30 | Alkermes Pharma Ireland Ltd | Morphinan derivatives for the treatment of drug overdose |
| US20110143704A1 (en) | 2009-12-14 | 2011-06-16 | William Lorentz | Specialized dial a chip |
| SI3446565T1 (sl) | 2010-08-23 | 2024-03-29 | Alkermes Pharma Ireland Limited | Metode zdravljenja povečanja teže, povzročene z antipsihotiki |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| US20140072936A1 (en) * | 2012-09-07 | 2014-03-13 | Patrick D. Herron | Method of Tracking Consumption and Associated Effects |
| JP2016519161A (ja) | 2013-05-24 | 2016-06-30 | アルカームス ファーマ アイルランド リミテッド | モルファン及びモルフィナン類似物及び使用の方法 |
| US9656961B2 (en) | 2013-05-24 | 2017-05-23 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
| RU2540911C2 (ru) * | 2013-06-11 | 2015-02-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами |
| DE102015202695A1 (de) * | 2015-02-13 | 2016-08-18 | Carl Zeiss Smt Gmbh | Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels |
| MA46778B1 (fr) | 2017-02-02 | 2022-08-31 | Otolanum Ag | Composition intranasale comprenant de la bétahistine |
| EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
| WO2024182465A2 (en) * | 2023-02-28 | 2024-09-06 | Alco Therapeutics, Llc | Methods for treating obsessive compulsive related disorders, tic disorders and glutamate excitotoxicity related disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1577871A (en) | 1976-05-28 | 1980-10-29 | Unimed Inc | Prevention of myocardial infarction |
| JPS55154915A (en) * | 1979-05-21 | 1980-12-02 | Jiyan Sadeia Shieruki | Medicine mold |
| US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| AU779264B2 (en) | 1998-12-23 | 2005-01-13 | G.D. Searle Llc | Combinations for cardiovascular indications |
| DE69939027D1 (de) * | 1998-12-23 | 2008-08-14 | Maxim Pharm Inc | Synthese von histamin-dihydrochlorid |
| IT1309591B1 (it) | 1999-03-05 | 2002-01-24 | Formenti Farmaceutici Spa | Composizioni a rilascio controllato di betaistina. |
| AU4598400A (en) * | 1999-05-19 | 2000-12-12 | Astrazeneca Ab | Method of treatment |
| ATE334659T1 (de) * | 2000-03-08 | 2006-08-15 | Awd Pharma Gmbh & Co Kg | Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung |
| US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| AU2002320025A1 (en) | 2001-04-11 | 2002-11-11 | Atherogenics, Inc. | Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| US20030162824A1 (en) | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
| US20040110803A1 (en) | 2002-09-13 | 2004-06-10 | Hossein Dovlatabadi | Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| CA2553309A1 (en) * | 2004-04-22 | 2005-11-03 | Mor Research Applications Ltd. | Method of food intake management |
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| US20080051440A1 (en) * | 2004-04-22 | 2008-02-28 | Mor Research Applications Ltd. | Compositions for weight management |
| US20060039867A1 (en) | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders with setiptiline |
-
2005
- 2005-04-21 CA CA002553309A patent/CA2553309A1/en not_active Abandoned
- 2005-04-21 WO PCT/IL2005/000440 patent/WO2005101979A2/en not_active Ceased
- 2005-04-21 KR KR1020067015532A patent/KR20060134041A/ko not_active Ceased
- 2005-04-21 JP JP2007509061A patent/JP2007533733A/ja active Pending
- 2005-04-21 EA EA200601414A patent/EA200601414A1/ru unknown
- 2005-04-21 BR BRPI0506807-0A patent/BRPI0506807A/pt not_active IP Right Cessation
- 2005-04-21 EP EP05734836A patent/EP1737454A4/en not_active Withdrawn
- 2005-11-22 US US11/283,865 patent/US20060084686A1/en not_active Abandoned
- 2005-11-22 US US11/283,928 patent/US7737165B2/en not_active Expired - Lifetime
-
2006
- 2006-07-11 IL IL176793A patent/IL176793A0/en unknown
- 2006-07-11 NO NO20063221A patent/NO20063221L/no not_active Application Discontinuation
-
2007
- 2007-08-03 US US11/882,677 patent/US20080004324A1/en not_active Abandoned
- 2007-08-03 US US11/882,740 patent/US20080004322A1/en not_active Abandoned
- 2007-08-03 US US11/882,678 patent/US20080051439A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007533733A5 (enExample) | ||
| EP3731870B1 (en) | Liquid oral formulations for pde v inhibitors | |
| JP2014528474A5 (enExample) | ||
| CA2450366A1 (en) | Controlled heat induced rapid delivery of pharmaceuticals from skin depot | |
| JP2010540519A5 (enExample) | ||
| JP2010530431A5 (enExample) | ||
| Quinn et al. | Novel methods of drug administration for the treatment and care of older patients | |
| CN102526043A (zh) | 透皮格拉司琼 | |
| TW201136916A (en) | New uses | |
| AU2017379247A1 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| CN111670050A (zh) | 用于治疗睡眠呼吸暂停的方法和组合物 | |
| US20200093737A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| WO2013173317A1 (en) | TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS | |
| JP2005511120A (ja) | 皮膚デポからの医薬品の制御された熱誘導迅速送達 | |
| US20090149518A1 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
| US20160287549A1 (en) | Novel methods for treating neurodegenerative diseases | |
| CN113194924B (zh) | 制备包含task-1和task-3通道抑制剂的药物剂型的方法及其在呼吸障碍治疗中的用途 | |
| JP5101191B2 (ja) | フィルム状製剤およびその製造方法 | |
| Frijlink | Benefits of different drug formulations in psychopharmacology | |
| JP2009539877A5 (enExample) | ||
| EP1772149A1 (en) | Drug for prevention or treatment of diabetes | |
| CN109999019B (zh) | 肉豆蔻脑酸甲酯在制备预防或治疗代谢综合征或改善机体能量代谢的产品中的应用 | |
| JP2021533192A (ja) | 薬剤を含む共晶溶媒、並びにその製造および使用方法 | |
| Babu et al. | Overview of formulation & evaluation of fast dissolving tablet: A promising tablet dosage form | |
| JP3948480B2 (ja) | いびき又は睡眠時の呼吸障害の予防・治療剤 |